Clinical trial
A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin
NCT00728936 is registered in ClinicalTrials.gov with Idera Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- May 31, 2010
- Enrollment
- 58 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.